Correction of neutrophil chemotaxis defect in patients with Gaucher disease by low-dose enzyme replacement therapy.
We have recently described a chemotactic defect in severely afflicted Gaucher disease patients. Two of the patients were treated with low-dose intravenous enzyme replacement (Ceredase). Marked improvement in their hematological status, organomegaly, and growth was observed. In addition, their chemotactic defect and their tendency towards infections were corrected within 1 year of treatment.
Zimran
A
A
Gaucher Clinic, Shaare-Zedek Medical Center, Jerusalem, Israel.
Abrahamov
A
A
Aker
M
M
Matzner
Y
Y
D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D002675:Child, Preschool; D005776:Gaucher Disease / Q000097:blood* / Q000188:drug therapy*; D005962:Glucosylceramidase / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D013997:Time Factors
C070292:alglucerase; D005962:Glucosylceramidase